Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2017

2017-05-31
Price :
Published : May-2017
No. of Pages : 53

GlobalData’s clinical trial report, “Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2017” provides an overview of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) clinical trials scenario. This report provides top line data relating to the clinical trials on Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Respiratory Syncytial Virus: Epidemiology Forecast in Asia-Pacific Markets to 2028

Respiratory Syncytial Virus: Epidemiology Forecast in Asia-Pacific Markets to 2028 Summary Respiratory syncytial virus (RSV) is a common respiratory infection that most children will be infected with by the time they are two years old. In healthy individuals RSV usually self-resolves within a week or two without need for significant therapeutic intervention. In preterm and very young infants, the elderly, or those with otherwise compromised immune systems, however, RSV can cause severe illness or death. It has been estimated that up to 30 million episodes of RSV-related lower respiratory infection occur annually worldwide, with the majority of those cases occurring in low-income countries. RSV is also considered to be the leading cause of bronchiolitis and pneumonia in children less tha......
$3495

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Turkey

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Turkey Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Turkey". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Turkey. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Turkey. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis......
$1995

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q2 2019

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2019 Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2019" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q2 2019. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides informatio......
$1500

Axial Spondyloarthritis – Epidemiology Forecast to 2028

Axial Spondyloarthritis - Epidemiology Forecast to 2028 Summary Axial spondyloarthritis (AxSpA) is a condition characterized by predominant inflammation in the spine and/or sacroiliac joints, with inflammatory back pain and stiffness that may be improved with exercise. Based on sacroiliac changes on conventional radiographs, AxSpA is classified into radiographic (r-AxSpA) or nonradiographic (nr-AxSpA) depending on the presence or absence of radiographic changes at the sacroiliac joints. Patients traditionally classified as ankylosing spondylitis (AS) would be considered as r-AxSpA. Some of nr-AxSpA progress to AS and some do not (Sieper et al., 2002; Kiltz et al., 2012; Wallis et al., 2013). AS has a genetic association with the HLA-B27 risk allele (Sieper et al., 2002; Dean et al., 2014......
$3995

Frontier Pharma – Small Cell Lung Cancer: Diverse First-in-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease

Frontier Pharma - Small Cell Lung Cancer: Diverse First-in-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease Summary Initially considered a curable disease due to substantial sensitivity to chemotherapy, small cell lung cancer (SCLC) remains a fatal disease with a poor outcome, with the majority of patients surviving one year or less after diagnosis. Unlike non-small cell lung cancer (NSCLC), in which major advances in treatment have been made following the approval of numerous targeted therapies, the field of SCLC has seen little advancement, and the standard of care (SOC) for several decades has been platinum-etoposide chemotherapy. Limited tumor tissue for translational research, poor understanding of the mechanisms underlying disease biology, and therapeu......
$6995

Gene Therapy in Neurology

Gene Therapy in Neurology Summary Gene therapy is an evolving area in healthcare that promises to revolutionize the treatment landscapes across various therapy areas. In this report, the focus will be on neurology indications. Recently approved gene therapies for spinal muscular atrophy have reinvigorated the potential of such therapies to transform patient care. While various methodologies can be adopted in order to deliver therapeutic benefits of gene therapy including gene augmentation, gene suppression, and gene editing, an important component of gene therapy is whether to use viral or non-viral vectors in order to deliver such therapies to the point of care. The report provides an analysis of the overall gene therapy pipeline that is being developed for various neurology indication......
$7995

Deal-Making Trends in Pharma – Thematic Research

Deal-Making Trends in Pharma - Thematic Research Summary To gain a better understanding of the pharmaceutical deal landscape, this report will dive into three separate deal categories: strategic partnerships, licensing activity, and M&A activity. Furthermore, the categories will be further broken down by four dominating therapeutic themes. These include gene therapy, immuno-oncology, microbiome, and orphan drugs. These themes are among those expected to have the greatest presence in deals made within the pharmaceutical industry, which is indicative of the optimism surrounding their future potential. Please also note that this report only covers select geographies, North America, Europe, and Asia-Pacific, the three regions with the highest deal volume and value. These regions were also c......
$1950

Myasthenia Gravis: Epidemiology Forecast to 2028

Myasthenia Gravis: Epidemiology Forecast to 2028 Summary Myasthenia gravis (MG) is the most common neuromuscular junction disorder, and is characterized by a fluctuating degree and variable combination of weakness in ocular, bulbar, limb, and respiratory muscles (Lai and Tseng, 2010). In this disease, receptors for acetylcholine at the neuromuscular junction are blocked, altered, or destroyed by the antibodies (immune proteins), which prevent the muscle from contracting. In some cases, antibodies to other proteins, such as the muscle-specific receptor tyrosine kinase (MuSK) protein, can also lead to impaired transmission at the neuromuscular junction (National Institute of Neurological Disorders and Stroke, 2017). GlobalData epidemiologists utilized historical data obtained from peer-re......
$3995

Ovarian Cancer: Opportunity Analysis and Forecasts to 2028

Ovarian Cancer: Opportunity Analysis and Forecasts to 2028 Summary Ovarian cancer is a rare gynecological disease that spans a broad range of genetic and histological subtypes, for which platinum-based chemotherapy has been the standard of care (SOC) for decades. Ovarian cancer can be broken down into many different types of neoplasms based on specific histopathologic entities and clinical behaviors, and treatment depends on the specific tumor type. Primary cytoreductive debulking surgery and platinum based chemotherapy form the SOC in advanced ovarian cancer. Roche's angiogenesis inhibitor Avastin (bevacizumab) is optionally used with SOC doublet chemotherapy, particularly in patients with late stage disease. In addition to Avastin, three poly-ADP ribose polymerase (PARP) inhibitors, A......
$10995

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Vietnam

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Vietnam Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Vietnam". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Vietnam. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Vietnam. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house ana......
$1995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy